Expression levels of ABCB1, ABCC1, Lung resistance-associated protein (LRP), ABCG2, p53, p21 waf1 , CD40L,, and O 6 -methylguanine-DNA-methyltransferase (MGMT) genes, and mutation of p53 gene were examined in 23 dogs with multicentric high-grade lymphoma to explore their association with drug resistance of the tumor cells. Dogs were divided into chemotherapy-sensitive (n=13) and -resistant (n=10) groups according to the response to a 6-month modified version of the University of Wisconsin (UW)-Madison chemotherapy protocol (UW-25), and expression levels of these factors and frequency of p53 gene mutation were compared between groups. No significant differences were observed in expression levels of each factor between groups. However, 4 dogs in the chemotherapy-resistant group showed high expression of ABCB1. No significant difference was observed in the frequency of p53 mutation between groups. A possible association of ABCB1 with resistance to UW-25 was shown, but no uniform mechanism associated with drug resistance could be identified in dogs with lymphoma.
Drug resistance is the most common cause of failure in chemotherapy for dogs with lymphoma. A number of factors associated with drug resistance have been studied in human and veterinary medicines [1, 20] . A number of molecules have been reported to contribute to the mechanisms of chemotherapy resistance of tumors in humans [11, 12, 15] . Such molecules are known to mediate reduced drug accumulation, decreased apoptosis, increased detoxification and increased DNA repair.
Various studies have been carried out to elucidate drug resistance in various tumors in humans. Over-expression of transport proteins including P-glycoprotein (P-gp) (the product of ABCB1, formerly called MDR1 gene [28] ), multidrug resistance-associated protein 1 (MRP1) (the product of ABCC1 gene [28] ), lung resistance-associated protein (LRP) [14] , and breast cancer-resistant protein (BCRP) (the product of ABCG2 gene [5] ) is known to be the major mechanism of reduced drug accumulation. Mechanisms of decreased apoptosis include aberrant of p53 gene and overexpression of Bcl-2 [4, 16, 19, 27] . Wild-type P53 has many functions, such as induction of a transient (cell cycle arrest) or permanent (senescence) blockage of cell proliferation and the activation of cell death pathways in response to genotoxic stress (apoptosis). In particular, in the regulation of the cell cycle, wild-type P53 promotes the expression of P21 WAF1 [17] . CD40L that is expressed on the T lymphocytes is known to promote the survival of the B-cell lymphoma cells through activation of CD40 on cancer cells [36] . Meanwhile, one recent study [35] reported coexpression of CD40 and CD40L on B lymphoma cells, suggesting its autocrine anti-apoptotic role. Increased detoxification is also considered to mediate drug resistance. Glutathione Stransferase (GST) acts to induce detoxification of cytotoxic drugs [26] . DNA repair pathways are also known to be involved in the development of drug resistance. O 6 -alkylguanine DNA alkyltransferase, which is encoded by O 6methylguanine DNA methyltransferase (MGMT) gene, has been reported to provide resistance to treatment with alkylating agents [3, 10, 31] .
In veterinary medicine, expression of P-gp was reported to be enhanced in cells of relapsed and chemotherapy-resistant dogs with lymphoma [2, 21, 25] , and expression of P-gp has been detected in a chemotherapeutic agent-resistant canine lymphoma cell line [34] . However, no report has described the association of ABCC1, LRP, ABCG2, p53, Bcl-2, CD40L, GST and MGMT gene with drug resistance in dogs with lymphoma. The objective of this study was to reveal correlations between these drug resistance factors and multidrug resistance in dogs with lymphoma by measuring expressions of ABCB1, ABCC1, LRP, ABCG2, p53, p21 waf1 , Bcl-2, CD40L, GST, and MGMT gene using a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) system and detecting p53 gene mutations.
MATERIALS AND METHODS

Animals:
We examined 23 dogs with age ranging from 2.7 to 11.8 years. Of the 23 dogs, 13 were females (9 spayed) and 10 were males (3 castrated . Twenty-one of the 23 dogs had been referred to the Veterinary Medical Center of the University of Tokyo, and the remaining 2 dogs had been referred to private veterinary hospitals and the samples were sent to our laboratory. All dogs were diagnosed with multicentric lymphoma based on cytological examinations of enlarged lymph nodes. According to the cytological examinations, the 23 dogs were diagnosed as high-grade lymphoma in the updated Kiel classification [8] . Lymphoma cell samples from all 23 dogs were shown to be clonally expanded B-lymphoid cells by PCR amplification test for the antigen receptor gene rearrangements as described previously [6] .
Evaluation of response to treatment: Veterinarians measured the size of the lymph nodes with calipers at each admission, and response to treatment was evaluated based on the new Response Evaluation Criteria in Solid Tumors (RECIST) [7] . In the evaluation of response to treatment, complete remission (CR) and partial remission (PR) were regarded as indicating chemotherapy-sensitive status, and stable disease (SD) and progressive disease (PD) were regarded indicating as chemotherapy-resistant status.
Treatment: A cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine, plus prednisolone (CHOP)-based chemotherapy, 6-month modified version of the University of Wisconsin (UW) -Madison chemotherapy protocol (UW-25) [9] , was used as a standard multidrug combination chemotherapy protocol. However, administration of Lasparaginase was omitted in most of the cases, because Lasparaginase (L-asp) has been reported to have no influence on the efficacy of the UW-25 protocol [24] . One dog of chemotherapy-resistant group received L-asp at week 1 of UW-25 protocol. All dogs that were enrolled in this study had not received any chemotherapeutic agent before the application of UW-25 protocol; however, three dogs in chemotherapy-sensitive group and two dogs in chemotherapy-resistant group had received corticosteroids for 1 day -1 month before chemotherapy.
Definition of patient groups: Chemotherapy-sensitive dogs were defined as those achieving CR or PR by week 5 of the UW-25 protocol. Tumor cell samples were collected just prior to the chemotherapy at the initial consultation. Chemotherapy-resistant dogs were defined as those that had underwent a relapse after achieving remission by UW-25 protocol and did not respond to all of the three chemotherapeutic agents used for UW-25, cyclophosphamide, doxorubicin, and vincristine. The tumor cell samples in the chemotherapy-resistant group were collected after confirming the non-responsiveness to these three drugs in conjunction with prednisolone after the relapse.
RNA extraction and reverse transcription: Total RNA was extracted from samples obtained by fine-needle aspiration (FNA) of neoplastic lymph nodes in dogs using RNAqueous (Ambion, Austin, TX, U.S.A.) and treatment with DNase I (Invitrogen, Carlsbad, CA, U.S.A.). To synthesize cDNA, total RNA was reverse transcribed using a PrimeScript TM RT reagent Kit (Perfect Real Time) (Takara Bio, Shiga, Japan).
Real-time PCR: Oligonucleotides complementary to the sequences of ABCB1, ABCC1, LRP, ABCG2, p53, p21 waf1 , Bcl-2, CD40L, GST and MGMT genes were designed using Primer3 software (http://frodo.wi.mit.edu/primer3/ input.htm). The mRNA sequences of factors other than the LRP gene were identified at Genbank, and that of LRP gene w a s i d e n t i f i e d a t E n s e m b l ( t r a n s c r i p t I D ENSCAFT00000026871, partial).
For normalization of the amount of cDNA sample, selection of the internal reference was carried out prior to the setting of quantitative analysis of the factors possibly related to the drug resistance. Candidates for an internal reference included TATA box binding protein (TBP), ribosomal protein L13a (RPL13A) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) genes [29] . Expressions of these three genes were quantified, and accuracies as internal control were analyzed using geNorm v 3.5 software (http:// medgen.ugent.be/~jvdesomp/genorm) [30] . From the result of this analysis, TBP gene was selected for use as an internal reference. The same primer pair for TBP gene was selected as in a previous report [29] . Sequences of the primers are listed in Table 1 . Amplification of products was confirmed by electrophoresis. Real-time PCR for quantification of mRNA for ABCB1, ABCC1, LRP, ABCG2, p53, p21 waf1 , Bcl-2, CD40L, GST and MGMT genes was performed using a Thermal Cycler Dice Real Time System TP800 (Takara Bio). Twenty-five microliters of the PCR mixture contained 12.5 l of Master Mix (SYBR ® Premix Ex Taq TM (Perfect Real Time)) (Takara Bio), 200 nM of sense and reverse primers, and 50 ng of cDNA. The cDNA samples were subjected to activation at 95C for 10 s, then 40 cycles of denaturation at 95C for 5 s, and annealing/extension at 62C for 30 s. After 40 cycles, samples were run using the dissociation protocol to verify the occurrence of a single melting peak. In this assay, 6-carboxyfluorescein (FAM) binds to double-stranded DNA, and increased fluorescence is detected. The results are expressed as the threshold cycle (C T ), that is, the cycle number at which increasing reporter fluorescence crossed a fixed threshold baseline.
For each factor and TBP gene, an assay-specific standard curve with serial (10 ) dilution of tumor cell cDNA from a dog with multicentric high-grade lymphoma was prepared. In these standard curves, the relative quantity of cDNA for each factor and TBP gene which was included in 50 ng of this cDNA sample was defined 10 5 . These standard curves were examined in triplicate. The relative quantity of each factor and TBP gene in lymphoma cells of dogs included in this study was calculated by plotting C T in the prepared standard curve. To normalize the amount of cDNA sample, the ratio of the relative quantity of cDNA for each factor to that of TBP gene was adopted. All samples were examined in duplicate.
Examination of mutation in p53 gene: The sequence of cDNA for p53 gene was divided into three fragments (fragments A, B and C) for PCR amplification and sequence analysis and three pairs of primers were selected for each of fragment A (nucleotides 2 to 479), fragment B (nucleotides 341 to 778), and fragment C (735 to 1,178), as described previously [32] . Primer sequences are listed in Table 2 . The cDNA of p53 gene for each dog was amplified by PCR using TaKaRa Ex Taq ® (Takara Bio) and primer pairs for each fragment. The cDNA samples were subjected to 30 cycles of denaturation at 98C for 10 s, annealing at 55C for 30 s and extension at 72C for 1 min. The sequence of each fragment was analyzed directly from PCR products using a BigDye terminator v3.1/1.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, U.S.A.) and Applied Biosystems 3130xl genetic analyzer (Applied Biosystems). When the sequence of cDNA of p53 gene fragment could not be analyzed directly, PCR products were inserted into a T/A cloning vector (pGEM-T Easy) (Promega Corporation, Leiden, The Netherlands), and subjected to sequence analysis. Ten clones from each cDNA sample were sequenced. To confirm aberration in function of P53 protein, relative quantities of p21 waf1 cDNA were compared between dogs that had mutations in p53 gene and those without mutations. Statistical analysis: Relative quantities of cDNA for each factor were compared between chemotherapy-sensitive and -resistant groups using the Wilcoxon rank-sum test. Relative quantities of p21 waf1 cDNA between dogs with p53 gene mutation and dogs with wild-type p53 gene were compared using the same test. In addition, frequency of mutation in the p53 gene was also compared between chemotherapysensitive and -resistant groups using Fisher's exact probability test. Values of P<0.05 were considered statistically significant. Statistical testing was performed using JMP version 5.0.1 (SAS Institute, Cary, NC, U.S.A.).
RESULTS
PCR amplification using primer pairs and accuracy of the real-time RT-PCR system: PCR amplification of cDNA samples with each primer pair yielded distinct bands of predicted size (Fig. 1 ). Analysis of dissociation curves revealed a single melting peak for each factor, indicating the specificity of primer pairs (data not shown). The accuracy of the real-time RT-PCR system developed in this study was examined for triplicate samples using cDNA synthesized from FNA samples used to make standard curves. In this study, differences  0.3 in C T were regarded as intra-assay error according to this examination. Ranges of r values and slopes of the standard curves for each drug resistance factors were 0.991~0.999 and -3.244 ~ -3.85, respectively. The variation in duplicate analyses was also  0.3 in C T , and the results were reasonably repeatable and precise.
Comparison of expression levels of factors between groups: Of the 23 dogs included in this study, 13 were chemotherapy-sensitive to the UW-25 protocol, and 10 were chemotherapy-resistant. No significant differences were observed in expression level of any factor between chemotherapy-sensitive and -resistant groups ( Table 3 and Fig. 2 ). However, high expression of ABCB1 was observed in 4 dogs in the chemotherapy-resistant group, with increases of 7-to 33-fold greater than the median relative quantity in the seisitive group.
Mutation in p53 gene: In 6 (26.1%) of 23 dogs, mutations in p53 gene were observed. Of these 6 dogs, 2 were chemotherapy-sensitive, and 4 were chemotherapy-resistant. Five dogs showed a missense point mutation in p53 gene (Cys 163 to Tyr, Arg 145 to Cys, Ser 114 to Pro, Arg 261 to Cys, and Arg 237 to Trp, respectively), and 1 dog showed a 1-base deletion (G, nt 453) resulting in introduction of a stop codon at codon 156 (Table 4 ). No significant difference was observed in the frequency of p53 gene mutation between chemotherapy- sensitive and -resistance groups. The relative quantity of p21 waf1 cDNA was significantly lower in dogs with p53 gene mutation than in those with wild-type p53 gene (P=0.02) ( Fig. 3 ).
DISCUSSION
In this study, no significant differences were observed between chemotherapy-sensitive and -resistant groups in relative quantities of mRNA for various genes known to have possible associations. Reasons for this result may include the fact that the relative quantities of cDNA for each factor varied among dogs. However, 4 dogs in the chemotherapy-resistant group showed high expression of ABCB1. Although the ABCB1 expression was conceivably associated with the resistance to UW-25, a possibility that the ABCB1 expression was a result of exposure to P-gp sub-strates such as doxorubicin and vincristine could not be excluded. Similar results were obtained in a previous report on canine lymphoma [25] , in which expression of P-gp protein was positive in 1 of 30 lymphoma tissues prior to chemotherapy, meanwhile it was positive in 3 of 8 lymphoma tissues at a phase showing chemotherapy resistance. In addition, two other studies on canine lymphoma [2, 21] showed that the P-gp expression was higher after relapse than before treatment, and the frequency of chemotherapyresistance might be high in the relapsed tissues. From the results in the present study in conjunction with those in previous reports, P-gp could conceivably be associated with resistance to chemotherapy in a subset of dogs with lymphoma. As shown in the study by Moore et al. [25] , less than half of chemotherapy-resistance canine lymphoma cases showed positive results for P-gp expression in the tumor tissues. In the present study, to try to understand the molecular mechanism that confers drug resistance on canine lymphoma cells, 10 kinds of the associated molecules were examined. However, any consistent change associated with the drug resistance could not be found; therefore, further effort is needed to know the drug resistance mechanism in canine lymphoma. In this study, the quantity of ABCB1 mRNA was measured by real-time RT-PCR, whereas in the previous three studies [2, 21, 25 ] P-gp expression was examined at the protein level. Kourti et al. [18] reported that high ABCB1 mRNA expression was correlated with the worse prognosis in childhood acute lymphoblastic leukemia. However, there is also a report which indicated that ABCB1 gene mRNA level in the lymphoma tissues did not correlate with the clinical response to doxorubicin in dogs [33] . Studies on the expression analysis in protein level are warranted with respect to a number of molecules possibly associated with drug resistance; however, it is problematic that antibodies cross-reacting with proteins of these canine counterparts are not necessarily available at a moment.
Although no significant correlations were observed in comparisons of the frequency of p53 gene mutation between chemotherapy-sensitive and -resistant groups, relative quantities of p21 waf1 cDNA were significantly lower in dogs with p53 gene mutations than in those with wild-type p53 gene (P=0.02). This result indicates a loss of function of the product from the mutated p53 gene compared to wild-type P53. However, the correlation between p53 gene mutation and drug resistance in dogs with lymphoma could not be identified and expression levels of p21 waf1 were not significantly different between chemotherapy-sensitive and -resistant groups. The p53 gene mutations found in the 2 chemotherapy-sensitive lymphoma patients prior to chemotherapy were considered to be generated through the molecular events to develop lymphoma. The mutations detected in 4 dogs in the chemotherapy-resistant group could be a result of exposure to chemotherapeutic agents or acquisition of drug resistance as well as the lymphomagenesis.
In the present study, the samples from chemotherapy-sensitive patients were obtained prior to chemotherapy, whereas those from chemotherapy-resistant patients were collected at the relapse when the patients had been already received chemotherapeutic agents. Therefore, the differences in the gene expression profile between the chemotherapy-sensitive and -resistant groups might be a result of the acquisition of chemotherapy-resistant characteristics or the exposure to chemotherapeutic agents. In a pretreatment phase, only a small proportion of dogs with lymphoma show resistance to chemotherapy. When it is possible, comparison of gene expression profile prior to chemotherapy between the chemotherapy-sensitive and -resistant groups would deny the influence of exposure to the drugs. In addition, the change of gene expression profile during the acquisition of drug resistance should be evaluated in individual dogs, because the variation of expression levels of each factor among dogs was large in this study. Considering these limitation in the present study, further effort is needed to accurately understand the molecular mechanism of drug resistance in dogs with lymphoma.
In conclusion, although a possible association of P-gp with chemotherapy resistance in canine lymphoma was indicated, no one factor could comprehensively explain chemotherapy-resistant in dogs with lymphoma. However, like P-gp in this study, chemotherapy resistance in individual cases seemed associated with some factors. Besides the factors examined in this study, factors such as extracellular matrix and growth factor are being studied in human medicine [23] . In addition, epigenetic changes in tumor cells [22] and the new concept of the cancer stem cell hypothesis have recently come into greater focus as mechanisms associated with drug resistance [13] . Further study examining individual changes of these factors in a greater number of dogs may be needed to identify the mechanisms of chemotherapy resistance.
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